Merck KGaA Sees Lackluster Earnings, Hurt by Generics

Merck KGaA forecast lackluster earnings in guidance that reflects generic competition for its multiple sclerosis blockbuster drug Mavenclad, but not the potential benefits from the US launch of a fertility medicine.

The forecast effectively writes off US Mavenclad sales for most of the year and excludes positive effects from a potential launch there of the fertility drug Pergoveris.